Targeted inhibition of SCF-SKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma
J. Wang, A. Ferrena, S. Singh, V. Viscarret, W. Al-Hardan, O. Aldahamsheh, H. Borjihan, A. Singla, S. Yaguare, J. Tingling, X. Zi, Y. Lo, R. Gorlick, E. L. Schwartz, H. Zhao, , B. H. Hoang
This study shows that inhibiting SKP2 in osteosarcoma reduces tumor growth and improves survival, suggesting it as a potential therapeutic target.
bioRxiv · May 13, 2023 · PreprintCancer Biology